CAR T-Cells for Hematologic Malignancies and Beyond

In this data-drenched discussion, UCSF specialists review how CAR T-cells are being used in hematologic malignancies, including aggressive lymphoma and difficult-to-treat myeloma, as well as for solid tumors, and reveal what's on the horizon with regard to these products. They discuss current options, including response rates; factors that put patients at risk for failure; and how challenges – such as transience and toxicity – may be overcome. They also look at problems with patient access that inform decision-making, including the timing of referral.

Related Presenters

Krishna Komanduri, MD.

Krishna Komanduri, MD

Professor and Chief, Division of Hematology and Oncology

Professor and Chief, Division of Hematology and Oncology, Dept. of Medicine; Physician-in-Chief, Helen Diller Family Comprehensive Cancer Center; Clinical Director, Living Therapeutics Initiative, UCSF View Full Profile

View Profile

Charalambos Andreadis, MD.

Charalambos Andreadis, MD


Dr. Charalambos (Babis) Andreadis specializes in bone marrow transplantation for adults and in treating Hodgkin's and non-Hodgkin's lymphoma, leukemia and multiple myeloma. He cares for patients at the UCSF Helen Diller Family Comprehensive ...

View Profile

Sandy Wong, MD.

Sandy Wong, MD


Dr. Sandy Wong is a blood disease specialist who cares for people with MGUS (monoclonal gammopathy of undetermined significance), smoldering myeloma, multiple myeloma and amyloidosis, a condition in which an abnormal protein called amyloid ...

View Profile

Julia Carnevale, MD.

Julia Carnevale, MD

Assistant Professor, Medicine

Dr. Carnevale is a physician-scientist who treats patients with gastrointestinal cancers, and also performs research into finding novel therapies for these diseases. View Full Profile

View Profile


Related Videos